A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age

A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age

Pneumococcal disease can be serious and debilitating in older adults. Pneumococcal conjugate vaccines (PCVs), such as the 13-valent PCV (PCV13), reduce pneumococcal disease rates caused by vaccine serotypes. Development of PCVs offering additional coverage against serotypes not contained in PCV13 ca...

Full description

Bibliographic Details
Main Authors: Brandon Essink, James Peterson, Kari Yacisin, Himal Lal, Sarah Mirza, Xia Xu, Ingrid L. Scully, Daniel A. Scott, William C. Gruber, Kathrin U. Jansen, Wendy Watson
Format: Article
Language:English
Published: Taylor & Francis Group 2021-08-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
clinical trial
pneumococcal conjugate vaccine
streptococcus pneumoniae
Online Access:http://dx.doi.org/10.1080/21645515.2021.1890511

Similar Items

Similar Items